Products for Research Use Only
RegisterLogin

DOTA-LM3

CAT: 0804-HY-P5126-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P5126-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo (D-Cys-Tyr-D-4-amino-Phe (carbamoyl) -Lys-Thr-Cys) D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis[1][2]. DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
CAS Number
1192362-32-5
UNSPSC
12352209
Target
Radionuclide-Drug Conjugates (RDCs) ; Somatostatin Receptor
Type
Peptides
Related Pathways
Antibody-drug Conjugate/ADC Related; GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dota-lm3.html
Purity
99.37
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL
Smiles
O=C([C@@H](NC([C@@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@@H](C(N)=O)CC2=CC=C(C=C2)O)=O)NC([C@@H](NC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)CC4=CC=C(C=C4)Cl)=O)=O)CC5=CC=C(C=C5)O)N[C@@H]1CC6=CC=C(C=C6)NC(N)=O
Molecular Formula
C69H93ClN16O19S2
Molecular Weight
1550.16
References & Citations
[1]Zhu W, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2022 Apr;49 (5) :1613-1622. |[2]Baum RP, et al. First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med. 2021 Nov;62 (11) :1571-1581.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
Phase 2
Isoform
RDC Peptide

Related Products

CatalogName
HY-P5362-01NODAGA-LM3
HY-P5362ANODAGA-LM3 (TFA)
HY-163040DOTA-Tyr-Lys-DOTA
HY-P11254DOTA-FAPT
HY-163039DOTA-biotin
HY-139564DOTA Zoledronate
HY-W802013DOTA-4AMP
HY-W038001DOTA-benzene
HY-P5128-01DOTA-JR11
HY-133540-01Maleimide-DOTA

Alternative Products

CatalogName
BA5818-1DOTA-LM3
A23503-10DOTA-LM3 10mg
T78110-01DOTA-LM3 TFA
A23503-5DOTA-LM3 5mg
A23503-1DOTA-LM3 1mg
MBS5821896NODAGA-LM3
MBS5821897NODAGA-LM3 TFA
GTR19267069-01DOTA-Tyr-Lys-DOTA
TRC-D535500-250MGDOTA
413907Gd-DOTA

Popular Products